Effects of Arzoxifene on Bone Mass and the Uterus

Postmenopausal Bone Loss Clinical Trial

Official title: Effects of Arzoxifene on Bone Mineral Density and Endometrial Histology in Postmenopausal Women.

Status Completed

Clinical Trial Summary

The purposes of this study are to determine:

• The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women.

• The effects of arzoxifene on the uterus (womb) in postmenopausal women.

• The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density.

• The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease risk.

• The safety of arzoxifene and any side effects that might be associated with its use.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Osteoporosis, Postmenopausal
• Postmenopausal Bone Loss

• NCT number: NCT00085956
• Study type: Interventional
• Source: Eli Lilly and Company
• Status: Completed
• Phase: Phase 3
• Start date: April 2004
• Completion date: February 2007